Angela Scheuerle
Pediatrics · Dallas, TXNPI 1073570586
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $113,522 of the $117,518 with a category attached, or 96.6%. 23 manufacturers reported payments, led by UCB SA at 47.9% of the total. Reporting peaked in 2024 at $29,910 and has fallen 60.1% since, to $11,922 in 2025. Among pediatrics clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 685 payments — averaging $171.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB SA$56K
- AbbVie$22K
- UCB Biosciences Inc.$6K
- Viiv Healthcare Company$6K
- Merck$6K
- Hikma Pharmaceuticals USA$4K
- plus $17K from 17 others
Across 430 payments — averaging $222.72 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Lupin Inc.$30K
- Novo Nordisk AS$17K
- Sanofi US Services Inc.$12K
- Teva Pharmaceuticals USA, Inc.$6K
- UCB, Inc.$5K
- Mylan Inc.$4K
- plus $22K from 10 others
What the payments were for
- Consulting fees$113,52297%
- Speaking & faculty fees$1,8462%
- Grants$7181%
- Travel & lodging$8611%
- Food & beverage$5700%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB SA | 70 | $56,250 |
| AbbVie | 104 | $22,247 |
| UCB Biosciences Inc. | 6 | $6,125 |
| Viiv Healthcare Company | 49 | $5,837 |
| Merck | 100 | $5,691 |
| Hikma Pharmaceuticals USA | 73 | $4,381 |
| Boehringer Ingelheim | 80 | $4,270 |
| Amneal Pharmaceuticals LLC | 59 | $3,889 |
| Sanofi US Services Inc. | 2 | $2,178 |
| Sandoz | 42 | $1,944 |
| Mylan Inc. | 34 | $1,438 |
| F. Hoffmann-la Roche AG | 13 | $990 |
| Gilead | 20 | $964 |
| Zydus Pharmaceuticals (USA) Inc. | 12 | $528 |
| Lupin Inc. | 6 | $288 |
| GSK | 2 | $180 |
| Sanofi | 4 | $112 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $106 |
| PTC Therapeutics, Inc. | 1 | $28 |
| Orchard Therapeutics North America | 1 | $26 |
| Sentynl Therapeutics, Inc. | 1 | $24 |
| Biomarin Pharmaceutical Inc. | 1 | $13 |
| Travere Therapeutics, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$117,518 in reported general payments places this provider in the 95th percentile of 5,361 pediatrics providers in Texas.
Other pediatrics in Dallas
- Ralph DeberardinisDallas$56K
- Anna SuessmanDallas$26K
- Marcial Oquendo RinconDallas$21K
- Albert KaramDallas$19K
- Pedro PiedraHouston$729K
- Jason RiehsFrisco$216K
- Ivonne Sahagun-CarreonNew Braunfels$168K
- Dianna BurnsSan Antonio$100K
- Jason TerkKeller$93K
- Vernon SuttonHouston$90K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.